IRulya Therapeutics Inc. (IRLA) Balance Sheet
IRLA balance sheet, 2025
December 31, 2025 · U.S. dollars$93.5M assets = $129.2M liabilities + −$35.7M equity
Liabilities exceed assets: shareholders’ equity is negative (−$35.7M).
Both columns are drawn to the same scale: what IRLA owns equals what it owes plus shareholders’ equity. Hover a block for its value.
IRLA financial health
Descriptive bands, not a rating. Fiscal 2025.
IRLA balance sheet trends, 2022–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $103.9M2022 | $93.5M2025 | −3.4%/yr | |
| Total liabilities | $3.3M2022 | $129.2M2025 | +239.0%/yr | |
| Shareholders’ equity | $100.6M2022 | −$35.7M2025 | — | |
| Cash & short-term investments | $90.2M2022 | $17.8M2025 | −41.8%/yr | |
| Total debt | $453,0002022 | $18.5M2025 | +244.2%/yr | |
| Net cash (debt) | $89.7M2022 | −$719,0002025 | −$90.4M | |
| Working capital | $90.7M2022 | −$20.3M2025 | −$111.0M | |
| Book value per share | $139.362024 | −$142.582025 | — | |
| Current ratio | 30.552022 | 0.532025 | −30.02 | |
| Debt / equity | 0.002022 | 0.492024 | +0.49 | |
| Shares outstanding | 216K2024 | 250K2025 | +15.8%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
IRLA assets
IRLA liabilities and equity
IRLA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
IRLA balance sheet
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | $17.8M | $40.8M | $75.1M | $90.2M |
| Cash & equivalents | $5.8M | $6.2M | $20.8M | $44.6M |
| Short-term investments | $11.9M | $34.6M | $54.3M | $45.6M |
| Receivables | $3.6M | $882,000 | $993,000 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other current assets | $1.5M | $2.4M | $1.4M | $3.6M |
| Total current assets | $22.9M | $44.0M | $77.4M | $93.7M |
| Property, plant & equipment (net) | $1.0M | $813,000 | $619,000 | $684,000 |
| Goodwill & intangible assets | $67.8M | $60.0M | $81.3M | $5.9M |
| Long-term investments | $78,000 | $78,000 | $78,000 | $3.6M |
| Other non-current assets | $1.7M | $9.5M | $20.8M | $0 |
| Total assets | $93.5M | $114.5M | $180.2M | $103.9M |
| Liabilities | ||||
| Accounts payable | $2.2M | $2.9M | $2.0M | $570,000 |
| Short-term debt | $18.1M | $96,000 | $64,000 | $453,000 |
| Total current liabilities | $43.2M | $7.3M | $9.6M | $3.1M |
| Long-term debt | $0 | $14.3M | $13.4M | $0 |
| Lease obligations | $445,000 | $490,000 | $385,000 | $453,000 |
| Other long-term liabilities | $86.0M | $62.7M | $72.1M | $248,000 |
| Total liabilities | $129.2M | $84.3M | $95.1M | $3.3M |
| Shareholders' equity | ||||
| Common stock & paid-in capital | $55,000 | $44,000 | $43,000 | $36,000 |
| Retained earnings (deficit) | −$460.5M | −$376.5M | −$319.6M | −$288.3M |
| Accumulated other comprehensive income | $5.8M | −$35,000 | $3.0M | −$289,000 |
| Total shareholders' equity | −$35.7M | $30.1M | $85.1M | $100.6M |
| Key figures | ||||
| Total debt | $18.5M | $14.8M | $13.8M | $453,000 |
| Net cash (debt) | −$719,000 | $26.0M | $61.2M | $89.7M |
| Working capital | −$20.3M | $36.8M | $67.9M | $90.7M |
| Tangible book value | −$103.5M | −$29.9M | $3.8M | $94.7M |
| Book value per share | −$142.58 | $139.36 | — | — |
| Shares outstanding | 250K | 216K | — | — |
| Current ratio | 0.53 | 6.05 | 8.09 | 30.55 |
| Quick ratio | 0.49 | 5.72 | 7.95 | 29.38 |
| Debt / equity | — | 0.49 | 0.16 | 0.00 |
| Equity / assets | −38.2% | 26.3% | 47.2% | 96.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & short-term investments | $116.0M | $18.2M | $17.8M | $26.3M | $34.7M |
| Cash & equivalents | $116.0M | $18.2M | $5.8M | $6.5M | $16.8M |
| Short-term investments | $0 | $11.9M | $11.9M | $19.8M | $17.9M |
| Receivables | $4.8M | $5.3M | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $2.7M | $2.1M | $5.1M | $2.9M | $2.6M |
| Total current assets | $123.4M | $25.6M | $22.9M | $29.2M | $37.3M |
| Property, plant & equipment (net) | $506,000 | $965,000 | $1.0M | $1.1M | $1.1M |
| Goodwill & intangible assets | $0 | $67.8M | $67.8M | $67.7M | $67.6M |
| Long-term investments | $78,000 | $78,000 | $78,000 | $78,000 | $78,000 |
| Other non-current assets | $0 | $0 | $1.7M | $11.8M | $11.1M |
| Total assets | $124.0M | $26.6M | $93.5M | $109.9M | $117.2M |
| Liabilities | |||||
| Accounts payable | $4.6M | $5.4M | $2.2M | $3.4M | $1.8M |
| Short-term debt | — | $113,000 | — | $17.6M | — |
| Total current liabilities | $8.5M | $8.8M | $43.2M | $26.0M | $7.5M |
| Long-term debt | $0 | $0 | $0 | $0 | $17.0M |
| Lease obligations | $0 | $406,000 | $445,000 | $473,000 | $499,000 |
| Other long-term liabilities | $7.0M | $2.2M | $86.0M | $82.8M | $81.0M |
| Total liabilities | $15.5M | $11.0M | $129.2M | $108.8M | $105.5M |
| Shareholders' equity | |||||
| Common stock & paid-in capital | $1,000 | $14,000 | — | $54,000 | — |
| Retained earnings (deficit) | −$500.0M | −$424.5M | −$460.5M | −$421.0M | −$407.6M |
| Accumulated other comprehensive income | $4.3M | $4.6M | — | $6.3M | — |
| Total shareholders' equity | $108.5M | $15.7M | −$35.7M | $1.1M | $11.7M |
| Key figures | |||||
| Total debt | — | $406,000 | — | $18.0M | $17.0M |
| Net cash (debt) | — | $17.8M | — | $8.3M | $17.7M |
| Working capital | $114.9M | $16.8M | −$20.3M | $3.2M | $29.9M |
| Tangible book value | $108.5M | −$52.1M | −$103.5M | −$66.7M | −$55.8M |
| Book value per share | — | $62.57 | −$128.18 | $3.93 | $43.77 |
| Shares outstanding | — | 250K | 279K | 270K | 268K |
| Current ratio | 14.52 | 2.92 | 0.53 | 1.12 | 5.00 |
| Quick ratio | 14.21 | 2.67 | 0.41 | 1.01 | 4.65 |
| Debt / equity | — | 0.03 | — | 16.99 | 1.45 |
| Equity / assets | 87.5% | 58.9% | −38.2% | 1.0% | 10.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed April 10, 2026); data from EODHD.
IRLA financial position
At the end of fiscal 2025 (December 31, 2025), IRulya Therapeutics had total assets of $93.5 million (down 18.3% from a year earlier), total liabilities of $129.2 million and shareholders' equity of -$35.7 million. It held $17.8 million in cash and short-term investments against $18.5 million of debt, net debt of $0.7 million. Its current ratio was 0.53. In the latest quarter (ended June 30, 2026) total assets were $124.0 million and equity $108.5 million.
Related: IRLA income statement, IRLA cash flow statement, IRLA key metrics. See the IRLA stock overview for the latest quote and news.
IRLA balance sheet FAQ
What are IRulya Therapeutics's total assets?
IRulya Therapeutics reported total assets of $93.5 million at the end of fiscal 2025 (December 31, 2025), compared with $114.5 million a year earlier.
How much debt does IRulya Therapeutics have?
IRulya Therapeutics had $18.5 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was —.
How much cash does IRulya Therapeutics have?
IRulya Therapeutics held $17.8 million in cash and short-term investments at the end of fiscal 2025; with $18.5 million of debt that is net debt of $0.7 million.
What is IRulya Therapeutics's book value?
IRulya Therapeutics's shareholders' equity (book value) was -$35.7 million at the end of fiscal 2025, or −$142.58 per share.
What is IRulya Therapeutics's current ratio?
IRulya Therapeutics had current assets of $22.9 million and current liabilities of $43.2 million, a current ratio of 0.53 (current liabilities exceed current assets).
How much goodwill does IRulya Therapeutics have?
IRulya Therapeutics carried $67.8 million of goodwill and intangible assets, 72.5% of total assets, at the end of fiscal 2025.